Atara Biotherapeutics Inc at Cowen HealthCare Conference Transcript
Good afternoon. Welcome once again to Cowen and Company's 40th Annual Health Care Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen and Company. And it's my pleasure to moderate a fire-side chat with Atara Biotherapeutics.
We're happy to have Pascal Touchon, the President and CEO, here with us today. Pascal, maybe you could start by giving a brief state of the company overview, what are the strengths and challenges of Atara today.
Thank you, Phil, and good to be here with you today. Clearly, for the 2019 has been a very busy year for Atara. We deliver on those expectations but 2020 is going to be very important year.
We have very clear milestones [to deliver] upon. And the way to look at that around today that we have diversified pipeline adding two programs at clinical stage; one in stage three, one in stage 1B, one in oncology, one in autoimmune disease in (inaudible)
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
